HRP20210228T1 - Amidi pirola kao inhibitori alfa v integrina - Google Patents
Amidi pirola kao inhibitori alfa v integrina Download PDFInfo
- Publication number
- HRP20210228T1 HRP20210228T1 HRP20210228TT HRP20210228T HRP20210228T1 HR P20210228 T1 HRP20210228 T1 HR P20210228T1 HR P20210228T T HRP20210228T T HR P20210228TT HR P20210228 T HRP20210228 T HR P20210228T HR P20210228 T1 HRP20210228 T1 HR P20210228T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- membered
- image
- carbocyclyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418833P | 2016-11-08 | 2016-11-08 | |
| EP17801236.5A EP3538528B1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
| PCT/US2017/060392 WO2018089360A1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210228T1 true HRP20210228T1 (hr) | 2021-03-19 |
Family
ID=60409438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210228TT HRP20210228T1 (hr) | 2016-11-08 | 2017-11-07 | Amidi pirola kao inhibitori alfa v integrina |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10717736B2 (OSRAM) |
| EP (1) | EP3538528B1 (OSRAM) |
| JP (1) | JP7220653B2 (OSRAM) |
| KR (1) | KR102515507B1 (OSRAM) |
| CN (1) | CN110139864B (OSRAM) |
| AU (1) | AU2017359030A1 (OSRAM) |
| BR (1) | BR112019009293A2 (OSRAM) |
| CA (1) | CA3042693A1 (OSRAM) |
| CY (1) | CY1123893T1 (OSRAM) |
| DK (1) | DK3538528T3 (OSRAM) |
| EA (1) | EA201991124A1 (OSRAM) |
| ES (1) | ES2852351T3 (OSRAM) |
| HR (1) | HRP20210228T1 (OSRAM) |
| HU (1) | HUE053620T2 (OSRAM) |
| IL (1) | IL266469A (OSRAM) |
| LT (1) | LT3538528T (OSRAM) |
| MX (1) | MX377293B (OSRAM) |
| PL (1) | PL3538528T3 (OSRAM) |
| PT (1) | PT3538528T (OSRAM) |
| RS (1) | RS61453B1 (OSRAM) |
| SI (1) | SI3538528T1 (OSRAM) |
| SM (1) | SMT202100089T1 (OSRAM) |
| WO (1) | WO2018089360A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
| EP3538526B1 (en) * | 2016-11-08 | 2024-04-10 | Bristol-Myers Squibb Company | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors |
| RU2019116820A (ru) | 2016-12-29 | 2021-01-29 | Сент-Луис Юниверсити | Антагонисты интегрина |
| EP4147698A1 (en) | 2017-02-28 | 2023-03-15 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| BR112019017929A2 (pt) | 2017-02-28 | 2020-05-19 | Morphic Therapeutic Inc | inibidores de integrina (alfa-v)(beta-6) |
| ES3019404T3 (en) | 2018-08-29 | 2025-05-20 | Morphic Therapeutic Inc | Integrin inhibitors |
| WO2020047208A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| WO2020092375A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| CN112996786B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| WO2022192545A1 (en) * | 2021-03-10 | 2022-09-15 | Dice Molecules Sv, Inc. | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類 |
| JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| JP2002511462A (ja) | 1998-04-10 | 2002-04-16 | ジー・ディー・サール・アンド・カンパニー | ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体 |
| WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
| AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
| DE19939981A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
| YU32502A (sh) * | 1999-11-08 | 2004-12-31 | Merck & Co.Inc. | Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina |
| GB0001447D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| AU2002243692B2 (en) | 2001-01-29 | 2006-06-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| WO2004020435A1 (en) | 2002-08-16 | 2004-03-11 | Janssen Pharmaceutica N.V. | Piperidinyl compounds that selectively bind integrins |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| ES2308227T3 (es) | 2003-10-01 | 2008-12-01 | Merck Patent Gmbh | Antagonistas de integrina alfavbeta3 y alfavbeta6 como agentes antifibroticos. |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| US20080045521A1 (en) | 2006-06-09 | 2008-02-21 | Astrazeneca Ab | Phenylalanine derivatives |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| US8481549B2 (en) * | 2010-01-19 | 2013-07-09 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US9518053B2 (en) * | 2013-02-07 | 2016-12-13 | Scifluor Life Sciences, Inc. | Fluorinated integrin antagonists |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
| WO2016145258A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
-
2017
- 2017-11-07 WO PCT/US2017/060392 patent/WO2018089360A1/en not_active Ceased
- 2017-11-07 HU HUE17801236A patent/HUE053620T2/hu unknown
- 2017-11-07 SM SM20210089T patent/SMT202100089T1/it unknown
- 2017-11-07 SI SI201730618T patent/SI3538528T1/sl unknown
- 2017-11-07 US US16/347,826 patent/US10717736B2/en active Active
- 2017-11-07 KR KR1020197016078A patent/KR102515507B1/ko active Active
- 2017-11-07 AU AU2017359030A patent/AU2017359030A1/en not_active Abandoned
- 2017-11-07 ES ES17801236T patent/ES2852351T3/es active Active
- 2017-11-07 PL PL17801236T patent/PL3538528T3/pl unknown
- 2017-11-07 HR HRP20210228TT patent/HRP20210228T1/hr unknown
- 2017-11-07 EA EA201991124A patent/EA201991124A1/ru unknown
- 2017-11-07 MX MX2019005233A patent/MX377293B/es active IP Right Grant
- 2017-11-07 RS RS20210206A patent/RS61453B1/sr unknown
- 2017-11-07 JP JP2019523772A patent/JP7220653B2/ja active Active
- 2017-11-07 BR BR112019009293A patent/BR112019009293A2/pt not_active Application Discontinuation
- 2017-11-07 CA CA3042693A patent/CA3042693A1/en not_active Abandoned
- 2017-11-07 PT PT178012365T patent/PT3538528T/pt unknown
- 2017-11-07 DK DK17801236.5T patent/DK3538528T3/da active
- 2017-11-07 LT LTEP17801236.5T patent/LT3538528T/lt unknown
- 2017-11-07 CN CN201780082138.2A patent/CN110139864B/zh active Active
- 2017-11-07 EP EP17801236.5A patent/EP3538528B1/en active Active
-
2019
- 2019-05-06 IL IL266469A patent/IL266469A/en unknown
-
2021
- 2021-02-23 CY CY20211100149T patent/CY1123893T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7220653B2 (ja) | 2023-02-10 |
| CY1123893T1 (el) | 2022-05-27 |
| CN110139864B (zh) | 2022-08-23 |
| US20190256512A1 (en) | 2019-08-22 |
| BR112019009293A2 (pt) | 2019-07-30 |
| PL3538528T3 (pl) | 2021-05-31 |
| WO2018089360A1 (en) | 2018-05-17 |
| EA201991124A1 (ru) | 2019-10-31 |
| SI3538528T1 (sl) | 2021-03-31 |
| PT3538528T (pt) | 2021-02-16 |
| RS61453B1 (sr) | 2021-03-31 |
| JP2020500182A (ja) | 2020-01-09 |
| LT3538528T (lt) | 2021-03-10 |
| IL266469A (en) | 2019-07-31 |
| EP3538528A1 (en) | 2019-09-18 |
| ES2852351T3 (es) | 2021-09-13 |
| CA3042693A1 (en) | 2018-05-17 |
| US10717736B2 (en) | 2020-07-21 |
| AU2017359030A1 (en) | 2019-06-20 |
| MX377293B (es) | 2025-03-07 |
| KR102515507B1 (ko) | 2023-03-28 |
| CN110139864A (zh) | 2019-08-16 |
| SMT202100089T1 (it) | 2021-03-15 |
| EP3538528B1 (en) | 2020-12-23 |
| DK3538528T3 (da) | 2021-02-15 |
| KR20190076031A (ko) | 2019-07-01 |
| MX2019005233A (es) | 2019-08-12 |
| HUE053620T2 (hu) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210228T1 (hr) | Amidi pirola kao inhibitori alfa v integrina | |
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| JP2020500182A5 (OSRAM) | ||
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| HRP20240861T1 (hr) | Derivati 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dihlorofenil)-2-metilpirimidin-4(3h)-ona i srodni spojevi kao inhibitori ptpn11 (shp2) za liječenje raka | |
| ME02373B (me) | Biciklična heterociklična jedinjenja kao inhibitori protein tirozin kinaze | |
| HRP20192147T1 (hr) | Metode i pripravci za uporabu u liječenju raka i smanjenju wnt posredovanih učinaka u stanici | |
| IL264982B (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| JP2016523974A5 (OSRAM) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2011511840A5 (OSRAM) | ||
| HRP20130041T1 (hr) | Terapijska sredstva | |
| JP2016530283A5 (OSRAM) | ||
| JP2019532928A5 (OSRAM) | ||
| HRP20200681T1 (hr) | Ciklički eter pirazol-4-il-heterociklil-karboksamidni spojevi i postupci njihove upotrebe | |
| HRP20120490T1 (hr) | Spojevi za inhibiciju napredovanja mitoze | |
| JP2015529235A5 (OSRAM) | ||
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| IN2014DN03063A (OSRAM) | ||
| HRP20211218T1 (hr) | Inhibitori receptora fibroblastnog faktora rasta | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| JP2017509689A5 (OSRAM) |